Healius (ASX: $HLS) Strategic Review Announcement

Healius Limited (ASX: $HLS) has announced the commencement of a comprehensive strategic review of its structure and assets. This follows the resignation of CEO & Managing Director, Ms Maxine Jaquet, who will be succeeded by the Company's CFO, Mr Paul Anderson. The strategic review aims to maximize shareholder value in response to the evolving diagnostics market and will be conducted in conjunction with the ongoing Pathology Transformation Reset Program.

Executive Commentary on Strategic Review and Leadership Change

Maxine Jaquet, the outgoing CEO & Managing Director, expressed gratitude to Healius' staff members and highlighted the company's crucial role during the Covid pandemic. She also acknowledged the team's dedication and lifesaving work. Ms Kate McKenzie, Healius' Interim Chair, commended Ms Jaquet for her leadership and announced the appointment of Mr Paul Anderson as the new CEO & Managing Director. Mr Anderson emphasized the expeditious yet efficient approach to the strategic review, aiming to maximize shareholder investment and capitalize on Healius' leading assets in imaging and pathology.

Summary of Healius Strategic Review and Leadership Change

Healius (ASX: $HLS) has initiated a strategic review of its assets and structure, coinciding with the resignation of CEO & Managing Director, Ms Maxine Jaquet, and the appointment of Mr Paul Anderson as her successor. The review, led by Mr Anderson, seeks to optimize Healius' operations and create shareholder value amidst industry disruption. The company aims to leverage its leading assets in imaging and pathology, including the growth prospects of businesses like Agilex. Healius remains committed to providing quality, affordable, and accessible healthcare for all Australians, with a focus on maximizing shareholder investment and adapting to the evolving diagnostics market.